Influenza Vaccination Acceptance and Refusal Rates Among Health Care Personnel

Millner, Vaughn S.; Eichold, Bernard H.; Franks, Ronald D.; Johnson, G. David

doi:10.1097/smj.0b013e3181eda3d5

Cited by 32 publications

(25 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, more than one-third of travellers refused influenza vaccine, which is recommended for all U.S. individuals who are 6 months of age or older without contraindications 19 . Previous studies have shown that U.S. adults refuse influenza vaccine at similar or even higher rates than our study participants, often due to lack of concern about the illness 20 , 21 …”

Section: Discussionmentioning

confidence: 59%

Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet

et al. 2016

View full text Add to dashboard Cite

Background: International travellers are at risk of travel-related, vaccine-preventable diseases. More data are needed on the proportion of travellers who refuse vaccines during a pre-travel health consultation and their reasons for refusing vaccines.Methods: We analyzed data on travellers seen for a pre-travel health consultation from July 2012 through June 2014 in the Global TravEpiNet (GTEN) consortium. Providers were required to indicate one of three reasons for a traveller refusing a recommended vaccine: (1) cost concerns, (2) safety concerns or (3) not concerned with the illness. We calculated refusal rates among travellers eligible for each vaccine based on CDC recommendations current at the time of travel. We used multivariable logistic regression models to examine the effect of individual variables on the likelihood of accepting all recommended vaccines.Results: Of 24 478 travellers, 23 768 (97%) were eligible for at least one vaccine. Travellers were most frequently eligible for typhoid (N = 20 092), hepatitis A (N = 12 990) and influenza vaccines (N = 10 539). Of 23 768 eligible travellers, 6573 (25%) refused one or more recommended vaccine(s). Of those eligible, more than one-third refused the following vaccines: meningococcal: 2232 (44%) of 5029; rabies: 1155 (44%) of 2650; Japanese encephalitis: 761 (41%) of 1846; and influenza: 3527 (33%) of 10 539. The most common reason for declining vaccines was that the traveller was not concerned about the illness. In multivariable analysis, travellers visiting friends and relatives (VFR) in low or medium human development countries were less likely to accept all recommended vaccines, compared with non-VFR travellers (OR = 0.74 (0.59–0.95)).Conclusions: Travellers who sought pre-travel health care refused recommended vaccines at varying rates. A lack of concern about the associated illness was the most commonly cited reason for all refused vaccines. Our data suggest more effective education about disease risk is needed for international travellers, even those who seek pre-travel advice.

show abstract

Section: Discussionmentioning

confidence: 59%

Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet

et al. 2016

View full text Add to dashboard Cite

show abstract

“…First, one goal of the World Health Organization is to have vaccines administered needle-free [39]–[43], such as nasal immunization, since the re-use of needles in developing countries contributes to the transmission of infectious diseases. Second, nasal immunization offers a beneficial alternative for patients with needle-phobia and may prevent their avoidance to vaccination [44]–[46]. Third, nasal immunization has the ability to induce antigen-specific secretory IgA (S-IgA) responses in mucosal secretions, while parenterally delivered vaccines rarely induce S-IgA [47]–[49].…”

Section: Discussionmentioning

confidence: 99%

Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits

et al. 2011

View full text Add to dashboard Cite

BackgroundWe previously reported that the immunogenicity of Hcβtre, a botulinum neurotoxin A (BoNT/A) immunogen, was enhanced by fusion to an epithelial cell binding domain, Ad2F, when nasally delivered to mice with cholera toxin (CT). This study was performed to determine if Ad2F would enhance the nasal immunogenicity of Hcβtre in rabbits, an animal model with a nasal cavity anatomy similar to humans. Since CT is not safe for human use, we also tested the adjuvant activity of compound 48/80 (C48/80), a mast cell activating compound previously determined to safely exhibit nasal adjuvant activity in mice.MethodsNew Zealand White or Dutch Belted rabbits were nasally immunized with Hcβtre or Hcβtre-Ad2F alone or combined with CT or C48/80, and serum samples were tested for the presence of Hcβtre-specific binding (ELISA) or BoNT/A neutralizing antibodies.ResultsHcβtre-Ad2F nasally administered with CT induced serum anti-Hcβtre IgG ELISA and BoNT/A neutralizing antibody titers greater than those induced by Hcβtre + CT. C48/80 provided significant nasal adjuvant activity and induced BoNT/A-neutralizing antibodies similar to those induced by CT.ConclusionsAd2F enhanced the nasal immunogenicity of Hcβtre, and the mast cell activator C48/80 was an effective adjuvant for nasal immunization in rabbits, an animal model with a nasal cavity anatomy similar to that in humans.

show abstract

“…Surveys used in earlier studies examining seasonal influenza vaccine compliance were used as the basis for this questionnaire. [21][22][23][24] In addition, questions were added that were specific to H1N1 influenza and this study's purposes. A group of 10 US influenza vaccine researchers provided feedback on content validity.…”

Section: Instrumentmentioning

confidence: 99%

H1N1 Influenza Vaccine Compliance among Hospital- and Non-Hospital-Based Healthcare Personnel

Rebmann

Iqbal

Anthony

et al. 2012

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

Influenza Vaccination Acceptance and Refusal Rates Among Health Care Personnel

Cited by 32 publications

References 19 publications

Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet

Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet

Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits

H1N1 Influenza Vaccine Compliance among Hospital- and Non-Hospital-Based Healthcare Personnel

Contact Info

Product

Resources

About